Anaphylaxis

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
CSL Limited, FDA, Investment, NDA, Research, MAA, CHMP, ASX, Trial of the century, ARS, PDUFA, European Medicines Agency, Patient, Adrenaline, Anaphylaxis, CSL, EMA, Caregiver, Committee, Allergy, Upper respiratory tract infection, CRL, Clinical trial, SAN, Journal, G&A

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the first quarter of 2024.

Key Points: 
  • Assuming approval on or before the anticipated PDUFA date, ARS Pharma anticipates launching neffy in the U.S. in the second half of 2024.
  • Following local regulatory approval of neffy, ARS Pharma will be responsible for supplying finished product to CSL Seqirus at a transfer price paid to ARS Pharma.
  • G&A expenses decreased from 2023 to 2024 primarily due to a pause in pre-commercial launch activities related to neffy.
  • Net Loss: Net loss was $10.3 million for the quarter ended March 31, 2024, compared to $15.0 million for the quarter ended March 31, 2023.

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Angioedema, FDA, Mouth, NDA, Food, Swelling, Skin, Research, Attention deficit hyperactivity disorder, Insurance, Trial of the century, ADHD, Lennox–Gastaut syndrome, Dermatology, Seizure, Prescription, Public expenditure, Riluzole, Vomiting, Patent, Patient, Adrenaline, Common stock, Anaphylaxis, Epilepsy, Diazepam, PD, Therapy, Serdexmethylphenidate/dexmethylphenidate, Type, Pharmaceutical industry

“We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Total revenues increased to $12.1 million in the first quarter 2024 from $11.1 million in the first quarter 2023.
  • Research and development expenses increased to $5.9 million in the first quarter 2024 from $3.5 million in the first quarter 2023.
  • Non-GAAP adjusted EBITDA loss was $7.2 million in the first quarter 2024, compared to non-GAAP adjusted EBITDA loss of $3.9 million in the first quarter 2023.

AAFA Co-Hosts Congressional Briefing Highlighting 25th Year of National Asthma Control Program

Retrieved on: 
Dienstag, Mai 7, 2024
Mortality, Public, Climate change, United, Allergist, Risk, CDC, Health, Pollen, Congress, NACP, Dingell, AAFA, Public policy, Food, Air pollution, Legislation, World Asthma Day, Anaphylaxis, Alaska Natives, Allergy, Atopic dermatitis, Quality of life, Polyp (medicine), Eosinophilic esophagitis, COVID-19, Calendar, RSV, Pharmaceutical industry

Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.

Key Points: 
  • Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma Day (May 7) by co-hosting a Congressional briefing highlighting the program’s impact and calling attention to the need to expand the program to all of the United States.
  • “The NACP provides resources for asthma education that help empower people with asthma,” said Kenneth Mendez, president and CEO of AAFA.
  • And for every $1 spent, the NACP saves $71 in total economic costs related to asthma.
  • On behalf of the 27 million people in the US with asthma, we’re grateful for the positive impact NACP has made over the past 25 years.

Multi Radiance Medical Renews Long-Term Global Sponsorship With ISELP

Retrieved on: 
Donnerstag, Mai 9, 2024
Veterinary, Other Manufacturing, Medical Devices, Pets, Health Technology, Manufacturing, Biotechnology, General Health, Consumer, Health, Relaxation, FDA, International Society, Veterinarian, Partnership, Light, Limp, DVM, Laser, Anaphylaxis, FEI, Horse, Medical imaging

Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .

Key Points: 
  • Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .
  • “As a leader in equine laser therapy, it is only fitting that we continue to partner with the highest level of equine veterinarians, and ISELP represents just that,” says Max Kanarsky, President and CEO of Multi Radiance Medical.
  • Kent Allen, DVM, ISELP board member and chair of the USEF Drugs and Medications Committee and Veterinarian Committee, says, "Science-based adjunctive treatments provide alternatives that help reduce drug-related side effects, making Multi Radiance an ideal partner."
  • I’m seeing reduced healing times, and improvements in healing in some cases unresponsive to a conventional approach.”
    To learn more about Multi Radiance and WellVu visit: https://info.multiradiance.com/vet/mrv_iselp

Allergy & Asthma Day Capitol Hill on May 8: Advancing Health Equity for All

Retrieved on: 
Mittwoch, Mai 1, 2024
Education, Congress, Law, Bangladesh Technical Education Board, Health equity, EPA, Investment, HELP, Risk, NIH, CDC, Allergy, Health, Collection, Research, Asthma, Native, Patient, Adrenaline, Legislation, Anaphylaxis, Clinical trial, Pharmaceutical industry

On May 8, Allergy & Asthma Network is hosting its 27th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC to advocate for healthcare policies and legislation that leave no one behind – regardless of race, ethnicity, education, income level or where they live.

Key Points: 
  • On May 8, Allergy & Asthma Network is hosting its 27th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC to advocate for healthcare policies and legislation that leave no one behind – regardless of race, ethnicity, education, income level or where they live.
  • The theme this year is "Breaking Barriers: Advancing Health Equity for All."
  • "Health disparities create barriers to accessing care and achieving optimal health," says Lynda Mitchell, CEO of Allergy & Asthma Network.
  • "We are excited to head back to Capitol Hill to advocate for legislation that is patient-first and reinforces health equity," says Charmayne Anderson, Director of Advocacy at Allergy & Asthma Network.

Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024

Retrieved on: 
Montag, April 29, 2024
Society, Murdoch Children's Research Institute, Health, Food allergy, MCRI, Parent, American Biographical Institute, Food, Patient, Anaphylaxis, Allergy, Research institute, Therapy, Peanut allergy, Woman, Pharmaceutical industry

MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards.

Key Points: 
  • MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards.
  • As the CEO of Prota Therapeutics, Professor Tang has demonstrated remarkable vision and resilience in advancing the company's mission to provide transformative treatments for food allergies.
  • "Receiving the 2024 Distinguished Leadership Award from the BioMelbourne Network is a tremendous honour.
  • The BioMelbourne Network Women in Leadership Awards celebrate individuals who demonstrate exceptional leadership qualities, contribute significantly to the health industry, and inspire positive change within the community.

Maryland Becomes Fourth State to Enact Elijah’s Law to Protect Kids with Food Allergies

Retrieved on: 
Freitag, April 26, 2024
Child care, Policy, Territory, Allergy, Asthma, Senate, AAFA, Food, Legislation, Interstate 95 in Maryland, Anaphylaxis, Memory, EAF, Nursing

Wes Moore, enacts policies designed to protect children with food allergies in child care centers.

Key Points: 
  • Wes Moore, enacts policies designed to protect children with food allergies in child care centers.
  • “We commend the state legislature for passing Elijah’s Law and taking steps to ensure uniform practices relative to food allergies in child care centers in Maryland,” said Kenneth Mendez, President and CEO of AAFA.
  • The bill ensures child care centers take steps to manage food allergies for the children in their care.
  • Maryland is the fourth state in the nation to pass Elijah’s Law, following New York, Illinois, and Virginia.

Global Skin Allergy Testing Market Report 2024: Revenue Data for 2020-2022, Estimated Figures for 2023, and Forecasts for 2028 - ResearchAndMarkets.com

Retrieved on: 
Freitag, April 26, 2024
Health, Other Health, Asthma, Allergic rhinitis, Allergic conjunctivitis, Drug allergy, Anaphylaxis, Hospital, Cosmetics

This report provides detailed information about the global skin allergy testing market.

Key Points: 
  • This report provides detailed information about the global skin allergy testing market.
  • It also analyzes the size of the skin allergy testing market based on test types, applications and end users.
  • Based on applications, the skin allergy testing market is segmented into allergic rhinitis, allergic asthma, drug allergy, allergic conjunctivitis, anaphylaxis and others.
  • Analysis of global market trends, featuring revenue data for 2020-2022, estimated figures for 2023, and forecasts for 2028.

Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

Retrieved on: 
Donnerstag, April 18, 2024
Medical Devices, Surgery, FDA, Clinical Trials, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Oncology, Urine, Society, Cancer, Hospital, Safety, Woman, NDA, New Drug Application, Surgeon, Breast, MD, Doctor of Philosophy, Patient, DVS, Anaphylaxis, Hypersensitivity, NEJM, Harvard Medical School, Multimedia, MD Anderson Cancer Center, Surgical oncology, Neoplasm, Massachusetts General Hospital, PMA, Breast cancer, Medical imaging

The most common side effects with LUMISIGHT are hypersensitivity and an abnormal color in urine.

Key Points: 
  • The most common side effects with LUMISIGHT are hypersensitivity and an abnormal color in urine.
  • Results of the Investigation of Novel Surgical Imaging for Tumor Excision (INSITE) pivotal trial, used to support the efficacy of the system, were published in NEJM Evidence .
  • “We want to thank our clinical investigators and the hundreds of women who participated in our breast program for LUMISIGHT and Lumicell DVS,” said Jorge Ferrer, Chief Scientific Officer, Lumicell.
  • “Due to your important contributions, LUMISIGHT and Lumicell DVS are now approved and will be available in the United States shortly.”
    Please visit www.LumiSystem.com to learn more about LUMISIGHT and Lumicell DVS.

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Retrieved on: 
Dienstag, April 16, 2024
Fetus, AMGN, American Thoracic Society, Congress, Arthralgia, ATS, Chronic obstructive pulmonary disease, Emphysema, Pregnancy, Infection, Tezepelumab, PDT, Allergic conjunctivitis, Amgen, Research and development, Back pain, Conference, Placentalia, Vaccine, Miscarriage, Development, Ageing, Helminthiasis, Incidence, Patient, Anaphylaxis, Hypersensitivity, Rash, Pharyngitis, Birth, Asthma, Bronchitis, AstraZeneca, Excipient, Pharmaceutical industry

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. 

Key Points: 
  • Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: −6, 36; p=0.1042).
  • Of note, more reductions were observed in a prespecified subgroup of patients with BEC ≥150 cells/μL (37% [95% CI: 7, 57]).
  • The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.
  • We look forward to presenting the full data set at the congress and based on these findings, we are actively planning for the Phase 3 development of tezepelumab in COPD.